Browse Articles

Discover research articles across all indexed journals

Liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.

Journal of Clinical Oncology Xuhua Hu, Bo Jiang, Lu Hongxia et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.195

195 Background: In patients with advanced colorectal cancer (CRC), the recommended second-line treatment following first-line therapy with oxaliplatin-based regimens is irinotecan-based therapy. Liposomal irinotecan, a novel formulation of traditional irinotecan, has demonstrated potential to enhance efficacy while minimizing toxicity. This study aims to investigate the efficacy and safety of liposomal irinotecan in combination with 5-FU/LV and bevacizumab as a second-line treatment option for metastatic CRC. Methods: This is a multi-center, single-arm, prospective, phase II study. Patients with metastatic CRC who received oxaliplatin-based chemotherapy as first-line treatment were enrolled to receive liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab regimen until disease progression and/or unacceptable toxicity. The primary endpoint is objective response rate (ORR), secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: A total of 50 patients were enrolled from Jan 2024 to Jul 2024 across 6 sites in China. The median age was 56.5 years (range: 30.0-76.0), with 58.0% male and 36.0% ECOG 0. Among the patients, 38.0% had left-sided colon cancer, 24.0% had right-sided colon cancer, and 38.0% had rectal cancer. As of Sept 14, 2024, 39 patients had at least one tumor assessment and 19 patients were still on treatment. ORR and DCR were 20.5% (8/39, 95% CI: 9.3%-36.5%) and 84.6% (33/39, 95% CI: 69.5%-94.1%), respectively. Eleven patients had disease progression and 5 patients died, and the median PFS and OS were not reached. The relative dose intensity of liposomal irinotecan and 5-fluorouracil were 92.8% (range: 23.6%-109.6%) and 89.5% (range: 13.3%-116.8%), respectively. During treatment, 43 (86.0%) patients had at least one adverse event (AE) and 24 (48.0%) had grade 3-4 AE. Most common (≥ 10%) grade 3-4 AEs were neutropenia (20.0%), leukocytopenia (16.0%) and diarrhea (10.0%). No unexpected toxicities observed in this study. Conclusions: These preliminary results reveled that liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab after oxaliplatin-based treatment for metastatic CRC was well tolerated with encouraging clinical activity, which warrants further follow up. Clinical trial information: NCT06184698 .

Observational study of the extent of lymph node metastasis among patients who underwent pancreatoduodenectomy for non-ampullary duodenal cancer using the National Clinical Database in Japan.

Journal of Clinical Oncology Yasuhiro Kodera, Masamichi Hayashi, Hiroyuki Yamamoto et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.798

798 Background: Non-ampullary duodenal cancer (NPDC) is a rare cancer that occurs in 0.3% of all cancers of the gastrointestinal tract. The first Japanese guidelines for this entity were published in 2021, and resection by pancreatoduodenectomy was weakly recommended as a standard treatment. Although presence of regional lymph node metastasis was identified as a prognostic factor among patients who underwent resection with curative intent, the recommendation concerning the optimal extent of lymphadenectomy based on big data was lacking. Methods: We conducted an observational study of patients who underwent pancreatoduodenectomy for NPDC between 2018 and 2021 in Japan, using the National Clinical Data (NCD) database. The NCD database is web-based, is linked with the board certification systems of several domestic surgical societies and covers >95% of the operations carried out by surgeons at 5,728 institutions in Japan. All cases of pancreatoduodenectomy for NPSC were retrieved from the NCD database after rigorously checking appropriateness of the patient selection, and surgeons in charge of these patients were invited by e-mails to fill in some additional data for this study during a time slot of Oct 2022 ~March 2023. Data thus obtained were the analyzed with particular focus on the incidence of metastases to each lymph node station, stratified by the tumor location in relation to the papilla. In addition, safety of surgery was compared between high-volume (institutions conducting ≥30 major hepatobiliary-pancreatic surgery) and low-volume (<30) hospitals. The study was funded in part by the Japanese Ministry of Health, Labor and Welfare as a project to create guidelines for rare cancers. Results: Data of 881 patients from 600 institutions were obtained for the analysis. Male constituted 68% and the median age was 70 years. The depth of invasion and presence of nodal metastasis were significant prognostic factors. The median number of lymph node retrieval was similar between the high-volume and low-volume hospitals (19: 95%CI 12~27 versus 18: 95% CI 11~25). Distribution of metastatic nodes depended on the location of tumor. Incidence of nodal metastasis exceeded 10% in lymph node station Nos. 5, 6, 7, 8 and 9 in cancers located on the oral side of the papilla. Thus, stomach-conserving pancreatoduodenectomy was considered appropriate only for cancers located distal to the papilla. The incidences of Grade IIIb~IVb complications (4% versus 7.1%), Grade V complications (0.4% versus 1.9%), and mortality within 30 days (0.4% versus 2.6%) were lower in high-volume hospitals. Conclusions: Stomach-preserving pancreatoduodenectomy is recommended only for NDPC located distal to the papilla. Centralization of surgery may be desirable.

Self‐Adaptive Dielectrics with Tunable Nonlinear Electrical Conductivity via Virus‐Like Structures Composed of Metal Particles

Advanced Materials Daoming Zhang, Congzhen Xie, Huasong Xu et al. Feb 01, 2025 DOI: 10.1002/adma.202411645

AbstractSelf‐adaptive dielectrics (SADs), with the characteristics of rapid charge dissipation in electric field distortion, is regarded as the future material for package insulation of advanced electronic devices. The current landscape of SADs is incapable to achieve tunable nonlinear electrical conductivity and threshold field strength due to the inherent Schottky barrier, significantly limiting the application scenarios of SADs. Here, a strategy is reported to construct a stepped Schottky barrier through virus‐like structures, which are composed of subminiature metal particles and semiconductor microspheres. It is found that the metal particles can serve as the capture center to attract the free charge in the matrix, precisely instructing the charge transfer pathway. The barriers between metal particles and semiconductor filler, flexibly controlled by the composition of metal particles, endow with extra source of nonlinear conductivity. Under the optimal composition and size of metal particles, SADs exhibit prominent nonlinear electrical conductivity and reliable adaptive charge release characteristics under pulsed electric field. The work pioneers a breakthrough by overcoming the constraint that SADs are previously limited to the inherent Schottky barrier of semiconductor materials and enabling the unprecedented controllability and flexibility of nonlinear electrical characteristics by metal particles, contributing a distinctive perspective to the development of SADs.

Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC).

Journal of Clinical Oncology Michael Cecchini, Manish R Sharma, Yasutoshi Kuboki et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.258

258 Background: Telisotuzumab adizutecan is an antibody-drug conjugate comprising the c-Met–targeting antibody telisotuzumab conjugated to a topoisomerase 1 inhibitor payload, adizutecan. A phase 1 trial (NCT05029882) in advanced solid tumors reported higher response rates in pts with CRC and high c-Met expression. We present an analysis of responses based on genomic alterations in ctDNA. Methods: Pts with CRC that is refractory to standard treatment were enrolled. Telisotuzumab adizutecan was given IV Q3W. ctDNA was isolated from baseline (BL) and cycle 3, day 1 plasma samples and analyzed with the GuardantINFINITY assay. Circulating tumor fraction (cTF) was estimated on the basis of variant allele frequency of somatic mutations in a 74-gene panel and methylation signals across targeted regions of the GuardantINFINITY methylation panel. Molecular response (MR) was defined as 50% decrease in cTF from BL. Radiographic response (RR) was assessed by RECIST v1.1. Results: Overall, 113 pts had both BL ctDNA and RR data. Confirmed ORR was 18% (20/113). The most prevalent gene alterations included TP53 (75%), APC (68%), and KRAS (66%) mut; PTPRT (56%), ASXL1 (53%), and FLT1 (52%) amp; SMAD4 (44%) and TP53 (43%) deletions; and MET (4%), BRAF , FGFR3, and NRG1 (all 3%) fusions. The Table shows RRs in pts with specific CRC biomarkers, and MR using the 2 panels with corresponding clinical outcomes. RRs were seen in pts with positive plasma samples at BL for TMB, RAS, BRAF, and HER2. MRs were detected in 64% and 65% of pts using the 74-gene and methylation panel, respectively. ORR was higher in pts with MR (35%) than without MR (8%) using the 74-gene, and 35% vs 0% using the methylation panel, respectively. Median PFS (mPFS) was longer in pts with MR. Conclusions: Telisotuzumab adizutecan has promising efficacy. RRs were seen in CRC pts with heterogeneous genomic profiles, including pts positive for actionable biomarkers in the metastatic setting. More pts with MR experienced RRs and benefited from treatment. Clinical trial information: NCT05029882 . Pts with ctDNA and radiographic response data(N=113) Radiographic cPR, n/N (%) 20/113 (18) Genomic alteration TMB a high ( ≥ 20 mut/Mb) KRAS mut KRAS G12C mut BRAF mut b HER2 amp cPR, n/N (%) Pos 11/48 (23) 11/73 (15) 1/5 (20) 4/14 (29) 2/9 (22) Neg 9/51 (18) 9/40 (23) 19/108 (18) 16/99 (16) 18/104 (17) MR, n/N (%) 74-gene panel 42/66 (64) Methylation panel 48/74 (65) ORR, n/N (%) MR pos 15/42 (36) MR neg 2/24 (8) MR pos 17/48 (35) MR neg 0/26 (0) mPFS, mo (95% CI) Events (n/N) 6.1 (5.3, 6.9)28/42 3.5 (2.6, 4.3)21/24 5.9 (5.3, 6.8)31/48 3.5 (2.7, 4.1)23/26 MR in pts with SD, n/N (%) 74-gene panel 27/45 (60) Methylation panel 31/53 (58) mPFS, mo (95% CI)Events (n/N) MR pos 5.3 (4.5, 5.9)21/27 MR neg 3.9 (2.8, 4.3)16/18 MR pos 5.3 (4.5, 5.9)23/31 MR neg 4 (2.8, 4.4)19/22 a 14 pts not evaluable for TMB. Threshold determined by Guardant. b 1 pt had V600E mutation. mo, months; neg, negative; pos, positive.

Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Journal of Clinical Oncology Peter Joel Hosein, Michael Rothe, Elizabeth Garrett-Mayer et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.715

715 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results from a cohort of pts with PC with BRCA1/2 mut treated with N+I are reported. Methods: Eligible pts had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options or prior immune checkpoint inhibitor tx. PD-L1 expression testing was not required. Genomic testing was performed in CLIA-certified, CAP-accredited site-selected labs. Most genomic tests did not distinguish between germline or somatic mut. Pts received I at 3 mg/kg every 3 weeks (wks) for 4 doses with N at 1 mg/kg IV every 3 wks for 4 doses. N alone was then continued at 240 mg every 2 wks or 480 mg every 4 wks until disease progression. Primary endpoint was disease control (DC) per investigator defined as complete (CR) or partial (PR) response per RECIST v. 1.1, or stable disease of at least 16 wks duration (SD16+). CR is based on radiographic assessment. CA 19-9 levels were not collected. Simon 2-stage design tested null DC rate of 15% vs. 35% (power = 0.85; α = 0.10). If ≥2 of 10 pts in stage 1 have DC, 18 more pts are enrolled; otherwise, the cohort is closed. If ≥7 of 28 pts have DC, the null DC rate is rejected. Secondary endpoints were objective response (OR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and SD, and safety. DOR is defined as time from pt’s first documented OR to progressive disease. Results: 32 pts with PC with BRCA1 (n=8), BRCA2 (n=22) or both BRCA1/2 (n=2) were enrolled between October 2017 and March 2023. 4 pts were not evaluable for efficacy. Pts had adenocarcinoma (n=29), acinar cell carcinoma (n=2), and poorly differentiated carcinoma (n=1). Table shows demographics and outcomes. 1 CR, 3 PR and 4 SD16+ were observed for a DC rate of 31% (90% CI, 18 to 100) and OR rate of 14% (95% CI, 4 to 33). The pt with CR had a BRCA1 mut, the pts with PR had BRCA1 (n=1) and BRCA2 (n=2) muts, and the pts with SD16+ had BRCA1 (n=2) and BRCA2 (n=2) muts. The null DC rate was rejected (p=0.04). The pt with CR remains on tx with a DOR of 311 wks as of May 2024. 15 pts received prior tx with olaparib and 1 of those pts had SD16+ on this study. 17 pts had ≥1 drug-related grade 3-4 adverse event (AE) or serious AE. All were consistent with N+I labels except generalized muscle weakness and lymphopenia. Conclusions: N+I shows antitumor activity in pts with PC with BRCA1/2 mut and warrants further study. Clinical trial information: NCT02693535 . Demographics (N=32) and efficacy outcomes (n=28). Median (Med) age, years (range) 66 (37-80) ECOG PS, % 0-12 31 (97)1 (3) Prior systemic regimens, % 0-2≥3 10 (31)22 (69) DC rate, % (OR and SD16+) (90% CI) 31 (18, 100) OR rate, % (95% CI) 14 (4, 33) Med PFS, wks (95% CI) 9 (7, 16) Med OS, wks (95% CI) 34 (14, 46)

Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

Journal of Clinical Oncology Hsiang-Lin Tsai Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.56

56 Background: Metastatic colorectal cancer (mCRC) poses a clinical challenge and requires a combination of systemic therapy and conversion surgery. Although first-line chemotherapy and target therapy are considered the standard treatments for mCRC, the role of primary tumor resection (PTR) in asymptomatic synchronous mCRC with unresectable metastatic lesion after initial therapy remains relatively underexplored. Methods: A retrospective observational study was conducted from January 2015 to January 2021, involving 74 patients with synchronous mCRC who received bevacizumab plus FOLFIRI as first-line systemic therapy. All 74 patients had unresectable metastatic lesions confirmed through multidisciplinary team (MDT) discussion. Patients' characteristics, PTR data, and radiotherapy (RT) and overall survival (OS) outcomes were analyzed. The patients were categorized into a "PTR" group and a "No PTR" group and then further stratified into IVA, IVB, and IVC subgroups based on the initial mCRC stage. Additionally, four subgroups - namely "PTR(+)/RT(+)", "PTR(+)/RT(-)", "PTR(-)/RT(+)", and "PTR(-)/RT(-)" were formed to assess the combined effects of PTR and RT. Results: The median OS for all the patients was 23.8 months (20.5 - 27.1 months). The "PTR" group exhibited a significantly higher median OS of 25.9 months (21.3 - 30.5 months) compared with 21.4 months (15.8 - 27.1 months) in the "No PTR" group ( P = 0.048). Subgroup analyses revealed a trend of improved survival with PTR in patients with stage IVA and IVB; however, the results were not statistically significant ( P = 0.116 and 0.493, respectively). A subgroup analysis of PTR and RT combinations revealed no significant difference in median OS rates. Conclusions: For asymptomatic mCRC with synchronous unresectable distant metastasis. PTR following first-line therapy with bevacizumab plus FOLFIRI can provide a survival benefit, particularly in stage IVA/IVB patients compared with stage IVC patients. Additionally, RT for primary tumor did not provide an additional OS benefit in mCRC with unresectable metastasis. A prospective randomized trial with a larger sample size is essential to further elucidate the role of PTR in this context.

High‐Efficiency Intrinsically Thermoplastic Semiconducting Polymer with Excellent Strain‐Tolerance Capacity for Flexible Ultra‐Deep‐Blue Polymer Light‐Emitting Diodes

Advanced Materials Mingjian Ni, Zhiqiang Zhuo, Yingying Zheng et al. Feb 01, 2025 DOI: 10.1002/adma.202411547

Abstract Complex internal stresses that appear in flexible thin‐film electronic devices under long‐term deformation operation are associated with incompatible mechanical properties of the multiple layers, which potentially cause intralayer fracture and separation. These defects may result in device instability, performance loss, and failure. Herein, a thermoplastic functional strategy is proposed for manufacturing high‐performance stretchable semiconducting polymers with excellent strain‐tolerance capacities for flexible electronic devices. Internal plasticization is used to obtain a thermoplastic light‐emitting polymer (N2) that can suppress intralayer tensile fracture and compressive separation to enhance the deformation stability of flexible thin‐film optoelectronic devices, enabling outstanding energy dissipation capacity under stress. The thermoplastic films exhibit stable and efficient ultra‐deep‐blue emission with a high efficiency of ≈90% and chromaticity coordinates of (0.16, 0.04). Moreover, the N2‐based rigid and flexible polymer light‐emitting diodes (PLEDs) exhibit stable ultra‐deep‐blue electroluminescence properties with high EQEs of ≈2.4% and 1.9%, respectively. Compared with devices based on brittle PODPF, flexible PLEDs based on thermoplastic films effectively suppress performance degradation after hundreds of cycles of bending fatigue, even under extremely rigid conditions. Introducing intrinsically thermoplastic semiconducting polymers in flexible electronic devices can thus substantially enhance their operational stability under deformation.

Retreatment with immune checkpoint inhibitors (ICIs) for patients with advanced gastric cancer: A retrospective, real-world study.

Journal of Clinical Oncology Yong-Xu Jia, Yihan Liu, Hui-Qiong Han et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.343

343 Background: Immunotherapy combined with chemotherapy has become the standard first-line treatment for advanced gastric cancer and is recommended by multiple guidelines and consensuses. After the first line immunotherapy, there is still controversy over whether immune inhibitors can continue to be used across lines after progression. Methods: This is a single-center, retrospective, observational, real-world study. We collected clinical information of patients with advanced gastric cancer hospitalized at the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024. All patients received combination therapy with ICIs inhibitors for at least 2 cycles in the first-line and at least 2 cycles of ICI inhibitor-based therapy in the second-line after first-line progression. The efficacy and safety of treatment were evaluated, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), the progression pattern of retreatment with immune checkpoint inhibitor, grade 3-5 treatment-related adverse events (TRAEs), and immune-related adverse events (irAEs). Cox regression model was used to investigate the influence of multiple factors on survival. Results: We included 217 patients with a median age of 59.0 (18-84) years, of which 70.0% were male. The median OS and PFS were 9.8 (95% CI 8.8-10.8) months and 4.6 (95% CI 4.0-5.3) months. The ORR and DCR were 22.7% (95% CI 17.1-29.0) and 56.2% (95% CI 49.0-63.1). For the second-line treatment regimens, there were 87 (40.1%) patients and 130 (59.9%) patients received immunotherapy combined with chemotherapy (I+C) and immunotherapy combined with chemotherapy and anti-angiogenic drugs(I+C+A) respectively. The median OS was 9.3 (95% CI 8.5-10.1) months and 11.5 (95% CI 9.3-13.7) months, p=0.032. The median PFS was 4.2 (95% CI 3.1-5.3) months and 5.2 (95% CI 4.3-6.1) months, p=0.082. Cox regression model analysis showed that ECOG 0-1, PFS≥6 months in the first-line treatment, second-line regimen (I+C+A), and second-line medication &gt; 3 cycles were independent prognostic factors for OS in the second-line treatment. The incidence of grade ≥3 TRAEs was 20.7%, and the incidence of irAEs was 6.5%. No treatment-related deaths occurred. Conclusions: This real-world study results showed that retreatment with immune checkpoint inhibitors had promising clinical benefit for patients with advanced gastric cancer and manageable safety. Efficacy of different groups.   n mOS(m) mPFS(m) ORR(%) DCR(%) ITT 217 9.8 4.6 22.7 56.2 ECOG 0-1 180 9.8 4.7 19.5 56.8 2 37 8.6 4.0 38.2 52.9 1-Line PFS <3m 61 5.5 2.2 1.7 17.2 ≥3m 156 11.7 6.0 31.0 71.7 <6m 136 7.4 3.2 2.4 38.7 ≥6m 81 15.1 8.0 54.4 83.5 Second-line treatment I+C 87 9.3 4.2 16.9 54.2 I+C+A 130 11.5 5.2 26.7 57.5 Second-line treatment cycle ≤3 97 7.4 2.9 4.8 31.0   >3 120 13.1 6.2 35.3 73.9

A method for classifying colorectal cancer and gastric/esophageal cancer using blood-based testing.

Journal of Clinical Oncology Elmira Forouzmand, Rachel Gittelman, Alan Selewa et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.52

52 Background: Identifying the cancer signal of origin is of great value in the clinical use of blood-based cancer testing, especially in those tests that have potential to assess for more than one cancer type. Thus, an approach that can accurately identify cancer signal of origin in order to guide subsequent diagnostic workup is impactful to the adoption of this new technology. Here, we report feasibility data using the DNA methylation signature of plasma cell-free DNA to differentiate between colorectal cancer (CRC) and gastric/esophageal cancer (GEC) types. Methods: We developed an algorithm to distinguish between CRC and GEC based on the DNA methylation signature of plasma cell-free DNA molecules from more than 3,000 differentially methylated regions. First, a regression model (a multi-cancer classifier) was trained to identify the samples with sufficient tumor derived methylation signal using 6,822 cancer samples of 24 cancer types and the samples from 4,423 cancer-free individuals. A second regression model (a CRC/GEC classifier) was trained to distinguish CRC from GEC cases on the samples with positive calls from the multi-cancer classifier. The second model was trained on methylation signals from advanced stage CRC samples, advanced stage GEC samples (including esophageal, gastroesophageal, and gastric cancers), and samples from cancer-free individuals. Results: The multi-cancer classifier identified 92% (2,954/3,204) of CRC and GEC samples as positive at 90% target specificity, including 93% (2,086/2,253) of CRC samples and 91% (868/951) of gastric/esophageal cancer samples. The performance of the CRC/GEC classifier is evaluated through 10-fold cross validation on these 3,204 cancer samples, where in each fold, an additional 6,298 samples from cancer-free individuals were also used in training. Among the 2,954 CRC and GEC samples detected by the multi-cancer classifier, 2,698 (91%) were accurately classified by the CRC/GEC classifier. Among the detected CRC samples, 91% (1,907/2,086) were correctly classified as CRC. Similarly, 91% (791/868) of the detected GEC samples were correctly classified. The precision of the CRC/GE prediction was also assessed and 91% (2,698/2,954) of the detected cancer samples were correctly classified. Of the 1,984 detected cancer samples predicted as CRC, 96% (1,907/1,984) were true CRC samples. Of the 970 detected cancer samples classified as GEC, 82% (791/970) were correct. Conclusions: This assay with high sensitivity and accurate CRC/GEC classification can effectively guide subsequent diagnostic workups following a positive result, maximizing potential clinical utility. Ongoing work will continue further refinements.

A protocol for pretreatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions.

Journal of Clinical Oncology Nicholas Della Marta, Alexander Yuile, Claire Mok et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.115

115 Background: Cetuximab has been shown to improve survival in patients with KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, with HSR rates up to 10-20%. A major driver of cetuximab HSR is from pre-formed antibody response to galactose-1,3-alpha-galactose (alpha-gal). Evidence from retrospective studies supports alpha-gal pre-screening in this setting. We are the first to report on the impact of prospective alpha-gal antibody screening on cetuximab HSR. Methods: Records were reviewed across three medical oncology centres that have adopted alpha-gal antibody screening measures. Data for patients with metastatic colorectal cancer treated with cetuximab were retrieved. All centres assessed alpha-gal antibody status using the ImmunoCAP ELISA assay. Due to lack of a shared screening approach across study sites, a pre-determined protocol was retrospectively applied to all cases. This protocol allowed cetuximab administration if alpha-gal levels were ≤0.1 kUA/L, but prohibited it if alpha-gal levels were &gt;0.1 kUA/L in favour of panitumumab administration. Patients were allocated to either the Protocol Applied or Protocol Not Applied cohorts based on protocol requirements being met. The primary outcome between these patient groups was the incidence of cetuximab HSRs. Results: Of 254 assessable patients, 39 underwent the pre-treatment screening protocol. Of the Protocol Applied group, 3% (n=1/38) experienced a cetuximab HSR compared to 16% (n=35/215) in the Protocol Not Applied group (Odds ratio (OR) 7.16; 95% CI 1.13–299.61, p =0.02). Patients with alpha-gal antibody titres &gt;0.1 kUA/L were more likely to experience a cetuximab HSR (OR 69.71; 95% CI 5.18–4296.81, p =0.0001). Conclusions: Pre-treatment screening for alpha-gal antibodies significantly reduces the incidence of cetuximab HSRs. A testing threshold of 0.1 kUA/L is effective in identifying patients at risk. Implementing this protocol can improve the safety of cetuximab therapy in high-risk populations.

Phytochlorin‐Based Sonosensitizers Combined with Free‐Field Ultrasound for Immune‐Sonodynamic Cancer Therapy

Advanced Materials Liu Wang, Lei Cao, Kun Shao et al. Feb 01, 2025 DOI: 10.1002/adma.202410559

AbstractPhytochlorins, a class of plant‐derived tetrapyrroles, show great potential as sonosensitizers in sonodynamic therapy (SDT). The development of new phytochlorin‐based sonosensitizers has significantly improved SDT, yet the absence of specialized sonodynamic systems limits their clinical translation. Herein, a dedicated ultrasound system along with a detailed step‐by‐step sonodynamic process from in vitro to in vivo is developed to activate phytochlorin‐based sonosensitizers. Compared to standing‐wave ultrasound, free‐field ultrasound maintains stable acoustic pressure amplitudes and minimizes mechanical damage to cell membranes. In vitro experiments demonstrate that free‐field ultrasound effectively activates naturally occurring phytochlorin, reducing the cavitation threshold for reactive oxygen species production and triggering immunogenic cell death. Furthermore, the intravenously injectable phytochlorin‐based sonosensitizer (C34) enhances sonodynamic efficiency by reducing interfacial tension. Driven by in vivo free‐field ultrasound, C34 effectively inhibits tumor growth in an orthotopic murine breast cancer model and elicits an immune response, preventing tumor metastasis. The reliable protocol provided by the free‐field ultrasound system facilitates the activation of phytochlorin‐based sonosensitizers while simultaneously stimulating the immune system, highlighting the potential of immune‐sonodynamic therapy.

Comprehensive landscape of FGFR variations and prognosis revelance in colorectal cancer from circulating tumor DNA and tissue gene analyses in 2083 patients.

Journal of Clinical Oncology Xiaoshuang Lyu, Runkai Cai, Bohan Han et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.278

278 Background: FGFR genomic alterations have been identified, and several FGFR inhibitors are approved for various malignancies, including bladder and cholangiocarcinoma. However, limited studies have shown FGFR alterations and their prognostic impact in colorectal cancer (CRC). Methods: This retrospective analysis involved tissue and blood samples from a single-institute cohort (The Sixth Affiliated Hospital of Sun Yat-sen University) of stage I-IV CRC patients from 2014 to 2024. FGFR genomic alterations were analyzed using tissue NGS and plasma ctDNA. Disease-free survival (DFS) for stages I-III and progression-free survival (PFS) for stage IV were compared between FGFR-altered and negative CRC patients, matched in a 1:2 ratio. Validation of genomic alterations and their prognostic impact was conducted using cBioPortal and TCGA data. Results: FGFR alterations were found in 7.89% of 608 tissue samples and 10.95% of 2083 ctDNA samples. The most frequent alteration was FGFR1 amplification in all cohorts, along with FGFR2 p.R165W and FGFR3 p.A634T mutations in ctDNA. FGFR alterations correlated with younger age, left-sided colon tumors, adenocarcinomas, poor differentiation, advanced TNM staging, and multi-organ metastasis. Prognostic analysis showed a higher proportion of FGFR alterations in stage IV patients (66.23% vs. 59.14%), lower rates of no evidence of disease (NED) (6.62% vs. 17.68%), and significantly shorter PFS (median 17 vs. 20 months, HR 2.184, p=0.007). In stages I-III, FGFR-altered patients also had a lower NED rate (79.22% vs. 82.19%) and significantly shorter DFS (median 13 vs. 29 months, HR 2.833, p=0.002). Among frequent alterations, FGFR1 amplification was significantly associated with poor prognosis (PFS 17 vs. 20 months, HR 2.221, p=0.014; DFS 13 vs. 29 months, HR 2.964, p=0.002), while others showed no significant correlation. In stage IV patients receiving bevacizumab, FGFR1 alteration was linked to significantly shorter PFS (p=0.0021). KEGG analysis indicated FGFR1 was associated with angiogenesis pathways. FGFR alteration profiles and prognostic outcomes were consistent across tissue samples, ctDNA analyses, and databases. Conclusions: Our study outlines the genomic landscape and prognostic significance of FGFR in CRC, highlighting FGFR1 amplification as the dominant alteration. FGFR alterations were associated with poorer outcomes, as reflected in lower NED rates and shorter DFS and PFS. FGFR1 amplification was notably linked to reduced DFS and PFS, and it correlated with shorter PFS in patients receiving bevacizumab, indicating a potential link to resistance against bevacizumab. ctDNA n=2083 Tissue genen=608 cBioPortal Databasen=6998 FGFR Total 228/10.95% 48/7.89% 528/8.0% FGFR1 76/3.65% 29/4.77% 264/4.0% FGFR2 78/3.74% 10/1.64% 125/1.9% FGFR3 104/4.99% 10/1.64% 139/2.1%

Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3.

Journal of Clinical Oncology Anjan J Patel, Ashley Ann Laursen, Paul Cockrum et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.716

716 Background: NALIRIFOX is approved by the US Food &amp; Drug Administration and European Medicines Agency for the first-line treatment of adults (no upper age limit) with mPDAC. Approval was based on the results of NAPOLI 3 (NCT04083235), in which NALIRIFOX demonstrated significant improvements in OS (primary outcome) and progression-free survival compared with nab-paclitaxel plus gemcitabine. In this exploratory post-hoc analysis of NAPOLI 3, we examined the impact of NALIRIFOX dose adjustments on OS in patients treated in North America. Methods: Patients (N = 770) with confirmed untreated mPDAC were randomized (1:1) to receive liposomal irinotecan 50 mg/m 2 + oxaliplatin 60 mg/m 2 + leucovorin 400 mg/m 2 + 5-fluorouracil 2400 mg/m 2 (NALIRIFOX) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m 2 and gemcitabine 1000 mg/m 2 on days 1, 8 and 15 of a 28-day cycle. In this analysis, liposomal irinotecan dose reductions, delays, and exposure were examined descriptively in patients who received NALIRIFOX at centers in North America. OS was evaluated using Kaplan–Meier methods; no statistical tests were performed. Results: Overall, 120 patients were randomized to receive NALIRIFOX at centers in North America (intention-to-treat [ITT] population) and 112 received treatment (safety population). Dose adjustments (dose reductions and dose delays) occurred in a higher proportion of patients presenting with longer OS. Patients with the longest duration of liposomal irinotecan exposure and highest cumulative dose had the longest OS. Conclusions: This finding suggests that tolerability-guided dose modification of liposomal irinotecan does not adversely affect efficacy outcomes and suggests a path forward to further optimize the OS of patients with mPDAC receiving NALIRIFOX. Clinical trial information: NCT04083235 .

Association between immune-related adverse events and prognosis after immune checkpoint inhibitor in hepatocellular carcinoma: A meta-analysis and systematic review.

Journal of Clinical Oncology Soo Young Hwang, Mohammad Saeid Rezaee-Zavareh, Abdelrahman M Attia et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.566

566 Background: Immune checkpoint inhibitors (ICIs) have become the preferred treatment for unresectable hepatocellular carcinoma (HCC). Conflicting data exist regarding the prognostic value of immune-related adverse events (irAEs) in these patients. We aimed to explore potential the association between irAEs and prognosis in HCC patients treated with ICIs. Methods: We searched PubMed, Scopus, Web of Science, and CENTRAL databases for articles published from inception to June 2024 using keywords including ICI, HCC, and irAEs. Two reviewers independently screened studies for eligibility and relevant data. A random effects model was used for statistical analysis, and subgroup analysis was performed by the grade of irAEs. Results: Of 3,028 studies, 25 (n=4,116 patients) met criteria for inclusion. Atezolizumab plus bevacizumab was the most common treatment regimen (n=10 studies). About half (49.5%) of patients experienced irAEs. irAEs were associated with increased objective response rate (ORR) (pooled OR: 1.72; 95% CI: 1.36 – 2.19, I 2 =39%), higher complete response rate (pooled OR: 1.45; 95% CI: 1.21-1.74, I 2 =74%), and longer progression-free survival (PFS) (pooled HR: 0.66; 95% CI: 0.52-0.84, I 2 =71%). Although irAEs were associated with longer overall survival, this difference was not statistically significant (pooled HR: 0.83; 95% CI: 0.62 – 1.11, I 2 =73%). Subgroup analysis showed a survival benefit for patients with grade 1-2 irAEs (pooled HR: 0.50; 95% CI: 0.36-0.67, I 2 =0%) but not for those with grade 3-4 irAEs (pooled HR: 0.95; 95% CI: 0.24-3.72, I 2 =84%). Conclusions: The development of irAEs is associated with a favorable prognosis in HCC, including improved PFS and higher ORR. A survival benefit was noted in patients with mild irAEs, but not in those with severe irAEs. Future studies are needed to determine if a differential survival benefit relates to the continuation vs. discontinuation of ICI therapy.

Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers.

Journal of Clinical Oncology Gentry Teng King, Kelsey K. Baker, Andrew L. Coveler et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.594

594 Background: The epidermal growth factor receptor (EGFR) and ErbB2/HER2 signaling is overactive in many solid tumors. Afatinib, an irreversible inhibitor of ErbB signaling, downregulates thymidine synthase and synergizes with capecitabine in preclinical models. This phase I trial evaluated the safety, maximum tolerated dose (MTD) and preliminary efficacy of afatinib plus capecitabine in patients (pts) with refractory solid tumors and pancreatic ductal adenocarcinoma (PDA) and biliary tract cancers (BTC). Methods: The phase I study had a 3+3 design with capecitabine 1000 mg/m 2 twice daily (BID) on days 1-14 and afatinib 20 mg, 30 mg or 40 mg daily (QD) in 21-day cycles. In phase Ib, 15 pts each with PDA and BTC were treated at MTD. Results: 41 pts enrolled from November 2016 to October 2021, who received a median of 2 (range 1-5) prior therapies. No dose-limiting toxicities were observed. The MTD was 40 mg afatinib QD plus 1000 mg/m 2 capecitabine BID. Grade 3 treatment related adverse events were diarrhea (12.2%) and nausea (4.9%). Among 36 response evaluable pts, best response was 1 partial response (PR, 3%) in a pt with KRAS wild type (WT)/EGFR amplified BTC, and 8 stable diseases (SD, 22%), with disease control rate (DCR) of 25%. PDA pts (n=20) had DCR of 24%, median progression-free (PFS) and overall survival (OS) of 1.9 months (95% CI 1.05, 2.03) and 3.2 months (95% CI 2.01, 5.82) respectively. BTC pts (n=18) had DCR of 31%, median PFS and OS of 1.9 months (95% CI 1.55, 3.39) and 4.6 months (95% CI 1.88, 6.09), respectively. Eight pts with cancers with EGFR/HER2/HER3 pathway alterations, most KRAS WT (n=6), had DCR of 29%, and median PFS and OS of 2.1 months (95% CI 1.05, 4.14) and 3.5 months (95% CI 1.64, 6.09), respectively. Conclusions: Afatinib plus capecitabine is tolerable but does not have significant efficacy in pts with refractory PDA/BTC, including in KRAS WT cancers with EGFR/HER2/HER3 alterations. Clinical trial information: NCT02451553 .

Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology Celine Hoyek, Binbin Zheng-Lin, Angelo Pirozzi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.277

277 Background: While HER2-targeted therapies benefit patients (pts) with advanced HER2-positive mCRC, the development of resistance remains inevitable. This study aims to explore the landscape and frequency of genetic alterations putatively associated with acquired resistance to anti-HER2 therapy in HER2-positive mCRC. Methods: In this retrospective-multicenter international study involving Mayo Clinic, Duke Cancer Center and National Cancer Center Hospital East (Japan), we descriptively compared comprehensive genomic analyses from tissue or blood samples of pts with HER2-positive CRC pre-treatment and post-treatment with HER2-targeting agents. Results: A total of 36 pts were included in this study. 29 (80%) had HER2-positive mCRC as confirmed by immunohistochemistry (IHC) and fluorescent in situ hybridization (ISH), the remaining pts had HER2 amplification detected on blood or tissue . 34/36 (94%) pts were administered their first anti-HER2 agent after progressing on ≥2 prior lines of treatment. The most common anti-HER2 regimen administered was trastuzumab/pertuzumab (50%, 18/36), followed by trastuzumab-tyrosine kinase inhibitors (TKIs) (tucatinib or neratinib) (30%, 11/36) and trastuzumab deruxtecan (14%, 5/36). Putative genomic mechanisms of acquired resistance were detected in 72% (26/36), while the remaining pts lacked new genomic alterations that might explain resistance to anti-HER2 therapy, suggesting alternative escape mechanisms. Acquired alterations in downstream or alternate bypass pathways were identified in 72% (26/36) of pts; most commonly in the RAS/RAF pathway and in EGFR (34.6%, 9/26 each), followed by 27% (7/26) of pts with MET point mutations (mts) and amplification; activating muts in PI3K/AKT and in 27% (7/26), most commonly CDK12 (60%, 4/7) . HER2 receptor alterations were detected in 3 pts (8.3%), all of whom received trastuzumab-tucatinib and included HER2 L755S, HER2 V777L, HER2 D769Y, HER2 G727A and HER2 S310F, which are known to cause resistance to , however, information about tucatinib resistance is not yet available. Other altered pathways included AR, RB, NOTCH and HRD. Two pts lost HER2 expression on blood and tissue NGS post anti-HER2 therapy. Conclusions: The emergence of resistance might be in part related to acquired alterations that constitutively activate signaling pathways parallel or downstream of HER2, bypassing HER2 inhibition. Additional histologic studies, deep mutational scanning, larger populations and correlative analysis are needed to validate these findings.

Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched comparison.

Journal of Clinical Oncology Chih Chieh Yen, I Shu Chen, Ying Jui Chao et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.396

396 Background: Perioperative triplet chemotherapy improves the survival and surgical outcome of patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in addition to curative surgery. 5-fluorouracil (5-FU), docetaxel, oxaliplatin and leukovorin (FLOT) has been suggested as the treatment of choice. S-1, an oral fluoropyrimidine chemotherapeutic, also shows compelling efficacy as one of the triplet backbone and is exempt from a prolonged infusion time. However, a comparison over efficacy and tolerability between S-1 or 5-FU-containing triplet has not been investigated. Methods: The study contains two parts. The first part was a prospective single-arm multi-centered phase II trial with eight cycles of perioperative leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with ≥T3 any N or ≥T2N(+) non-metastatic gastric/GEJ adenocarcinoma. The primary endpoint was the treatment response assessed by pathological tumor regression (TRG). After confirming the result passing the statistical threshold, we compared them with an identical and independent patient population who received perioperative FLOT under a prospective observation. A propensity score matching (PPSM) was used to balance the heterogeneity between the two groups. The efficacy, survival and tolerability were compared in a post-hoc manner. Results: From Feb 2017 to Jan 2024 with a comparable median follow-up time (LOTS, 18.7 ms; FLOT, 18.9 ms), a total of 45 and 154 patients were enrolled and received either LOTS or FLOT treatment. After a one-to-two PPSM procedure, the baseline characteristics of patients were comparable (LOTS, n=45; FLOT, n=90). Patients had similar curative resection rates (LOTS, 91%; FLOT, 86%; p=.359) and above nearly complete pathological regression rates (TRG 0-1: LOTS, 23%; FLOT, 27%; p=.669). The 24-ms recurrence-free (RFS) and overall survival (OS) rates were also comparable (LOTS vs. FLOT: 66 vs. 59% in RFS, p=.463; 73 vs. 68% in OS, p=.491). The toxicities were tolerable, except that more diarrhea and nausea events were reported in the LOTS group, whereas neutropenia, thrombocytopenia and mucositis were significantly prominent in the FLOT group. Conclusions: Perioperative LOTS shows reasonable therapeutic efficacy and survival as compared with FLOT in patients with locally advanced gastric/GEJ cancer. While the toxicity profile is distinctive from FLOT, it could be a potential alternative regimen with the convenience to save the prolonged infusion time. Clinical trial information: NCT04999332 . Pathological outcome. Prior to LOTS treatment (n=45) After LOTS treatment (n=43) Prior to FLOT treatment (n=90) After FLOT treatment (n=86) p in LOTS vs. FLOT CAP TRG, n (%) 0.669 0 - - 1 (2.3) - - 3 (3.5) 1 - - 9 (20.9) - - 20 (23.3) 2 - - 14 (32.6) - - 23 (26.7) 3 - - 19 (44.2) - - 40 (46.5)

An Analysis of Components and Enhancement Strategies for Advancing Memristive Neural Networks

Advanced Materials Hyungjun Park, Joon‐Kyu Han, Seongpil Yim et al. Feb 01, 2025 DOI: 10.1002/adma.202412549

AbstractAdvancements in artificial intelligence (AI) and big data have highlighted the limitations of traditional von Neumann architectures, such as excessive power consumption and limited performance improvement with increasing parameter numbers. These challenges are significant for edge devices requiring higher energy and area efficiency. Recently, many reports on memristor‐based neural networks (Mem‐NN) using resistive switching memory have shown efficient computing performance with a low power requirement. Even further performance optimization can be made using engineering resistive switching mechanisms. Nevertheless, systematic reviews that address the circuit‐to‐material aspects of Mem‐NNs, including their dedicated algorithms, remain limited. This review first categorizes the memristor‐based neural networks into three components: pre‐processing units, processing units, and learning algorithms. Then, the optimization methods to improve integration and operational reliability are discussed across materials, devices, circuits, and algorithms for each component. Furthermore, the review compares recent advancements in chip‐level neuromorphic hardware with conventional systems, including graphic processing units. The ongoing challenges and future directions in the field are discussed, highlighting the research to enhance the functionality and reliability of Mem‐NNs.

Patterns of immune checkpoint inhibitor utilization and PD-L1 testing in advanced gastroesophageal cancers using real-world data.

Journal of Clinical Oncology Jasmeet Kaur, Li Zhang, Jill S. Hasler et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.370

370 Background: Globally, gastroesophageal cancer (GEC) is a leading cause of morbidity and mortality, with poor 5-year overall survival (OS). The addition of immune checkpoint inhibitors (ICIs) such as nivolumab and pembrolizumab to chemotherapy has resulted in significant improvement in OS of those patients (pts) with metastatic GEC (mGEC), most notably in those with tumors exhibiting high PD-L1 CPS scores. However, the pattern of ICI utilization in associated PD-L1 testing since the adoption of this treatment (tx) has yet to be elucidated. We evaluated the patterns of ICI utilization and PD-L1/CPS testing in the first-line tx of mGEC pre and post FDA approval of ICI use in this setting. Methods: Pts ≥ 18 years of age, with recurrent/metastatic squamous or adenocarcinoma GEC diagnosed after 2011 were included from the de-identified nationwide Flatiron Health, electronic health record-derived database. We presented the proportion of pts receiving ICI therapy, stratified by line of tx, as well as the proportion of patients who received PD-L1 testing at 6-month intervals. Pts demographics and clinical characteristics, including age, gender, race, ECOG score, documented insurance, and stage at diagnosis (dx) were described and compared using T or Wilcoxon rank-sum tests for continuous variables, and chi-square or Fisher’s exact tests for categorical data. We compared tx rates and PDL-1 testing across four time points: time 1: Jan-June 2020, prior to ASCO data presentation; time 2: July-Dec 2020, ASCO data presentation; time 3: Jan- June 2021, FDA label change; time 4: July 2021 to 6 m after FDA label change using Chi-square test. Results: A total of 9,573 pts were included with 1,593 (16.6%) receiving ICI-based tx. Among these, 62.3% were White, 7% Black. Descriptive statistics indicated that pts with ICI- tx tend to be younger (median age 65y vs. 66.7; (p &lt;0.001). Within the total cohort, 74% pt were dx before FDA approval of ICI tx, while 26% pts were dx after FDA approval. PD-L1 testing was conducted in 4,065 (42.5%) pts. A total of 1,268 (13%) pts received first-line ICI-based tx. Of these, 154 pts (12.1%) were treated before FDA approval, while 1,114 pts (87.9%) received tx following FDA approval. The rate of first-line ICI tx significantly increased at each subsequent time point Time 2: 11.2% (p &lt;0.0001), Time 3: 32.9% (p &lt;0.0001), Time 4: 37.4% (p &lt;0.0001). PD-L1 testing rates also increased over time, particularly after FDA label change. Testing rates at Time 1 was 68%. Comparatively, testing rates at subsequent time points were: Time 2 (67.2%; p 0.88), Time 3 (71.5%; p 0.324) and Time 4 (77.4%; p=0.004). Conclusions: The approval of ICIs for first-line tx of mGEC led to a significant increase in both ICI utilization and PD-L1/CPS testing rates. Despite these advancements, ongoing disparities in tx access and testing highlight the need for further research and efforts to ensure equitable care.

Evaluation of CSF1R as a potential prognostic biomarker in colorectal cancer (Alliance).

Journal of Clinical Oncology Sandra Algaze, Yan Yang, Joshua Millstein et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.285

285 Background: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in colorectal cancer (CRC) outside of mismatch repair (MMR) deficient/microsatellite instability-high (MSI-H) tumors. Most CRC cases are MMR proficient /microsatellite stable and demonstrate resistance to ICIs, attributed to the tumor microenvironment. Colony Stimulating Factor 1 Receptor (CSF1R), a regulator of tumor-associated macrophages, has emerged as a potential target due to its association with poor prognosis in CRC. Methods: Data from 433 metastatic CRC (mCRC) patients in the CALGB/SWOG 80405 trial were analyzed. CSF1R RNA was extracted from formalin-fixed, paraffin-embedded tumor samples and sequenced. Patients were divided into tertiles of CSF1R expression (high, medium, low). Progression-free survival (PFS) and overall survival (OS) were compared using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. Subgroup analyses were conducted based on liver metastases, treatment type (Bevacizumab, Cetuximab, FOLFOX, FOLFIRI), and MSI status. Results: Low CSF1R expression (CSF1R-L) was associated with significantly better survival outcomes. Median PFS was 12.9 months for CSF1R-L, compared to 11.2 and 9.2 months for CSF1R-M and CSF1R-H (p = 0.003). Median OS was 35.8 months for CSF1R-L versus 32.5 and 24.4 months for CSF1R-M and CSF1R-H (p = 0.00086). Stratification by liver metastases showed that CSF1R-L remained a strong prognostic factor only in patients with liver metastases. There were no significant survival differences based on CSF1R expression in bevacizumab-treated patients. However, in cetuximab-treated patients, CSF1R-L tumors had significantly longer PFS (12.9 vs 8.8 months, p = 0.037) and OS (35.8 vs 21.4 months, p = 0.002) than CSF1R-H tumors. Similarly, in FOLFOX-treated patients, CSF1R-L tumors showed longer PFS and OS (p = 0.018 and p = 0.013, respectively), and in FOLFIRI-treated patients, OS was significantly longer for CSF1R-L tumors (42.2 vs 24.7 months, p = 0.022) than CSF1R-H tumors. Conclusions: Our data suggests that CSF1R expression may serve as a prognostic biomarker in CRC, with lower expression potentially linked to improved survival, particularly in patients with liver metastases. These findings warrant further investigation of CSF1R as a possible prognostic and predictive biomarker, as well as a potential therapeutic target in CRC. Clinical trial information: NCT00265850 .